pharmaphorum

JANUARY 19, 2023

A regimen of Roche’s Tecentriq and Avastin has become the first immunotherapy-based combination to reduce the risk of liver cancer returning after surgery to remove the tumour in a phase 3 trial, according to the company. Overall, liver cancer is the third leading cause of cancer death.

Antibody 52

Antibody Trials Drugs 52

The Pharma Data

JUNE 25, 2021

First-Time Disease-Free Survival Data to be Presented During Plenary Session at the 2021 ASCO Annual Meeting. 41.5), KEYTRUDA demonstrated a statistically significant and clinically meaningful reduction in the risk of disease recurrence or death by 32% compared to placebo (HR=0.68 [95% CI, 0.53–0.87]; KENILWORTH, N.J.–(BUSINESS

HR 52

HR Trials Clinical Research Research 52

The Pharma Data

DECEMBER 20, 2020

Many companies appear to be getting their clinical trial news updated ahead of the holidays. They are being treated with Vyrologix (leronlimab-PRO 140), a CCR5 antagonist that has potential for multiple therapeutic indications, including HIV and metastatic triple-negative breast cancer. Here’s a look. COVID-19-Related.

Trials 52

Trials Gene Therapy Vaccination Vaccine 52